Multivariate analysis indicates that disease-specific survival of individuals with advanced laryngeal cancer was improved for those receiving neoadjuvant therapy.
The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.
Approximately 25% to 30% of breast cancers are the result of the overexpression of the HER2 gene.
Patients with initially unresectable pancreatic cancer might experience clinical benefits from neoadjuvant therapy, according to a study published in PLoS Medicine (2010 Apr 20;7(4):e1000267).
